FDAnews
www.fdanews.com/articles/178379-nice-rebukes-reimbursement-for-roches-combination-therapy-for-melanoma

NICE Rebukes Reimbursement for Roche’s Combination Therapy for Melanoma

September 12, 2016

The UK’s price watchdog recommended against the reimbursement of Roche’s Cotellic and Zelboraf for the treatment of BRAF V600 mutation-positive melanoma, citing the expensive list price for the products.

In a final appraisal, the UK’s National Institute for Health and Care Excellence noted that the combination improved survival, but added that the cost of treatment is “substantially over the range usually considered a cost-effective.”

The clinical need for the combination of drugs is limited, because of the breadth of treatment options available, NICE said.

View today's stories